Dsp Healthcare Fund Datagrid
Category Pharma Fund
BMSMONEY Rank -
Rating
Growth Option 27-04-2026
NAV ₹38.86(R) +2.38% ₹43.33(D) +2.39%
Returns 1Y 3Y 5Y 7Y 10Y
Lumpsum Regular 3.98% 22.19% 13.59% 20.74% -%
Direct 5.37% 23.84% 15.14% 22.5% -%
Nifty Pharma TRI 6.53% 23.67% 12.57% 14.52% 8.22%
SIP (XIRR) Regular -12.79% 7.12% 13.2% 16.8% -%
Direct -11.58% 8.67% 14.8% 18.52% -%
Ratio Sharpe Ratio Sortino Ratio Sterling Ratio Jensen's Alpha Treynor Ratio
0.88 0.47 0.84 -0.62% -0.48
Risk STD. Dev VaR 1Y95% Max DD Beta Semi Devi.
15.16% -19.54% -13.57% 0.82 10.52%
Fund AUM As on: 30/12/2025 3140 Cr
Top Pharma Fund
Fund Name Rank Rating
Mirae Asset Healthcare Fund -
Aditya Birla Sun Life Pharma & Healthcare Fund -
Uti Healthcare Fund -
Sbi Healthcare Opportunities Fund -
Icici Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund -
Nippon India Pharma Fund -
Tata India Pharma & Healthcare Fund -

NAV Date: 27-04-2026

Scheme Name NAV Rupee Change Percent Change
DSP Healthcare Fund - Regular Plan - IDCW 22.51
0.5200
2.3800%
DSP Healthcare Fund - Direct Plan - IDCW 25.06
0.5900
2.3900%
DSP Healthcare Fund - Regular Plan - Growth 38.86
0.9000
2.3800%
DSP Healthcare Fund - Direct Plan - Growth 43.33
1.0100
2.3900%

Review Date: 27-04-2026

Beginning of Analysis

The Dsp Healthcare Fund has shown a very good past performence in Pharma Fund. The Dsp Healthcare Fund has a Jensen Alpha of -0.62% which is lower than the category average of 0.91%, showing poor performance. The Dsp Healthcare Fund has a Sharpe Ratio of 0.88 which is lower than the category average of 1.01, showing poor performance.
The past performance of the {fund_name_eng} may or may not be sustained in the future. The review is not investment advice nor is it a recommendation to buy or sell funds.
Pharma Mutual Funds

Dsp Healthcare Fund Return Analysis

The Dsp Healthcare Fund has delivered a mixed performance across various time horizons, showcasing both strengths and challenges when compared to its Pharma Fund peers and the Nifty Pharma TRI benchmark. This analysis examines the fund’s returns over periods ranging from one month to ten years, alongside its Systematic Investment Plan (SIP) performance, highlighting its rankings within the Pharma Fund category and its ability to outperform or underperform the benchmark and category averages.

  • The fund has given a return of 7.18%, 4.58 and -1.1 in last one, three and six months respectively. In the same period the category average return was 5.54%, 8.48% and 1.08% respectively.
  • Dsp Healthcare Fund has given a return of 5.37% in last one year. In the same period the Nifty Pharma TRI return was 6.53%. The fund has given 1.16% less return than the benchmark return.
  • The fund has given a return of 23.84% in last three years and rank 7th out of eight funds in the category. In the same period the Nifty Pharma TRI return was 23.67%. The fund has given 0.17% more return than the benchmark return.
  • Dsp Healthcare Fund has given a return of 15.14% in last five years and category average returns is 15.71% in same period. The fund ranked 6.0th out of eight funds in the category. In the same period the Nifty Pharma TRI return was 12.57%. The fund has given 2.57% more return than the benchmark return.
  • The fund has given a SIP return of -11.58% in last one year whereas category average SIP return is 6.88%. The fund one year return rank in the category is 15th in 15 funds
  • The fund has SIP return of 8.67% in last three years and ranks 8th in 8 funds. Mirae Asset Healthcare Fund has given the highest SIP return (17.04%) in the category in last three years.
  • The fund has SIP return of 14.8% in last five years whereas category average SIP return is 17.02%.

Dsp Healthcare Fund Risk Analysis

  • The fund has a standard deviation of 15.16 and semi deviation of 10.52. The category average standard deviation is 15.97 and semi deviation is 11.32.
  • The fund has a Value at Risk (VaR) of -19.54 and a maximum drawdown of -13.57. The category average VaR is -19.09 and the maximum drawdown is -14.79. The fund has a beta of 0.8 which shows that fund is less volatile than the benchmark.

Standard deviation measures the fund's return volatility and Semi deviation focuses on downside volatility. Value at Risk (VaR) is a measure of the risk of investments. Maximum Drawdown is the maximum loss from a peak to a trough of a portfolio. Beta measures the volatility of the fund compared to the benchmark. A beta of 1 indicates that the fund will move in line with the benchmark. A beta of more than 1 indicates that the fund will be more volatile than the benchmark and vice versa.


  • Very Good Performance in Pharma Fund Category
  • Good Performance in Pharma Fund Category
  • Poor Performance in Pharma Fund Category
  • Very Poor Performance in Pharma Fund Category

    • Investors beware: Mutual Fund investments are subject to market risks. Please read the scheme related documents carefully.

    Data Source: www.amfiindia.com

    SEBI Categorization


    KPIs* Fund Nifty Pharma TRI Cat. Avg Min | Max Rank (In Cat.) Performance
    1M Return % 7.06 2.69
    5.42
    		2.60 | 7.15 2 | 16 Very Good
    3M Return % 4.25 6.59
    8.12
    		4.25 | 11.19 16 | 16 Poor
    6M Return % -1.75 4.11
    0.40
    		-2.94 | 5.68 13 | 16 Poor
    1Y Return % 3.98 6.53
    6.10
    		1.55 | 12.86 11 | 15 Average
    3Y Return % 22.19 23.67
    24.07
    		22.19 | 27.24 8 | 8 Poor
    5Y Return % 13.59 12.57
    14.32
    		12.78 | 16.25 7 | 8 Poor
    7Y Return % 20.74 14.52
    19.85
    		18.31 | 21.28 3 | 7 Good
    1Y SIP Return % -12.79
    5.47
    		-12.79 | 14.48 15 | 15 Poor
    3Y SIP Return % 7.12
    12.85
    		7.12 | 15.67 8 | 8 Poor
    5Y SIP Return % 13.20
    15.62
    		13.20 | 18.24 8 | 8 Poor
    7Y SIP Return % 16.80
    17.85
    		16.28 | 19.78 6 | 7 Average
    Standard Deviation 15.16
    15.97
    		14.75 | 16.83 2 | 8 Very Good
    Semi Deviation 10.52
    11.32
    		10.52 | 12.07 1 | 8 Very Good
    Max Drawdown % -13.57
    -14.79
    		-16.36 | -12.33 2 | 8 Very Good
    VaR 1 Y % -19.54
    -19.09
    		-23.30 | -15.67 6 | 8 Average
    Average Drawdown % -3.72
    -5.48
    		-6.79 | -3.72 1 | 8 Very Good
    Sharpe Ratio 0.88
    1.01
    		0.85 | 1.20 7 | 8 Poor
    Sterling Ratio 0.84
    0.92
    		0.79 | 1.09 7 | 8 Poor
    Sortino Ratio 0.47
    0.53
    		0.43 | 0.63 7 | 8 Poor
    Jensen Alpha % -0.62
    0.91
    		-2.04 | 4.20 7 | 8 Poor
    Treynor Ratio -0.48
    -0.43
    		-0.48 | -0.40 8 | 8 Poor
    Modigliani Square Measure % 21.46
    23.67
    		20.89 | 27.07 7 | 8 Poor
    Alpha % -2.91
    -1.43
    		-3.34 | 1.08 7 | 8 Poor
    Return data last Updated On : April 27, 2026.
    Other parameters, fund ranking, non return related analysis are updated after every month end. Last Updated On : March 30, 2026
    KPIs: Key Performance Indicators

    Rotate the phone! Best viewed in landscape mode on mobile.
    KPIs* Fund Nifty Pharma TRI Cat. Avg Min | Max Rank (In Cat.) Performance
    1M Return % 7.18 2.69 5.54 2.75 | 7.29 2 | 16 Very Good
    3M Return % 4.58 6.59 8.48 4.58 | 11.59 16 | 16 Poor
    6M Return % -1.10 4.11 1.08 -2.08 | 6.28 13 | 16 Poor
    1Y Return % 5.37 6.53 7.52 3.04 | 14.20 11 | 15 Average
    3Y Return % 23.84 23.67 25.53 23.61 | 28.33 7 | 8 Poor
    5Y Return % 15.14 12.57 15.71 14.39 | 17.28 6 | 8 Average
    7Y Return % 22.50 14.52 21.30 19.93 | 22.61 2 | 7 Very Good
    1Y SIP Return % -11.58 6.88 -11.58 | 15.81 15 | 15 Poor
    3Y SIP Return % 8.67 14.24 8.67 | 17.04 8 | 8 Poor
    5Y SIP Return % 14.80 17.02 14.80 | 19.27 8 | 8 Poor
    7Y SIP Return % 18.52 19.29 18.04 | 20.88 5 | 7 Average
    Standard Deviation 15.16 15.97 14.75 | 16.83 2 | 8 Very Good
    Semi Deviation 10.52 11.32 10.52 | 12.07 1 | 8 Very Good
    Max Drawdown % -13.57 -14.79 -16.36 | -12.33 2 | 8 Very Good
    VaR 1 Y % -19.54 -19.09 -23.30 | -15.67 6 | 8 Average
    Average Drawdown % -3.72 -5.48 -6.79 | -3.72 1 | 8 Very Good
    Sharpe Ratio 0.88 1.01 0.85 | 1.20 7 | 8 Poor
    Sterling Ratio 0.84 0.92 0.79 | 1.09 7 | 8 Poor
    Sortino Ratio 0.47 0.53 0.43 | 0.63 7 | 8 Poor
    Jensen Alpha % -0.62 0.91 -2.04 | 4.20 7 | 8 Poor
    Treynor Ratio -0.48 -0.43 -0.48 | -0.40 8 | 8 Poor
    Modigliani Square Measure % 21.46 23.67 20.89 | 27.07 7 | 8 Poor
    Alpha % -2.91 -1.43 -3.34 | 1.08 7 | 8 Poor
    Return data last Updated On : April 27, 2026.
    Other parameters, fund ranking, non return related analysis are updated after every month end. Last Updated On : March 30, 2026
    KPIs: Key Performance Indicators

    Disclaimer: Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments. Returns for periods above 1 year are annualised.


    Date Dsp Healthcare Fund NAV Regular Growth Dsp Healthcare Fund NAV Direct Growth
    27-04-2026 38.862 43.334
    24-04-2026 37.959 42.322
    23-04-2026 38.253 42.649
    22-04-2026 37.923 42.28
    21-04-2026 37.641 41.963
    20-04-2026 37.858 42.204
    16-04-2026 37.586 41.894
    15-04-2026 37.687 42.006
    13-04-2026 37.079 41.325
    10-04-2026 36.948 41.174
    09-04-2026 36.741 40.942
    08-04-2026 36.721 40.919
    07-04-2026 36.151 40.282
    06-04-2026 35.998 40.11
    02-04-2026 35.999 40.105
    01-04-2026 36.319 40.461
    30-03-2026 35.974 40.073
    27-03-2026 36.299 40.43

    Fund Launch Date: 12/Nov/2018
    Fund Category: Pharma Fund
    Investment Objective: The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
    Fund Description: An open ended equity scheme investing in healthcare and pharmaceutical sector
    Fund Benchmark: S&P BSE HEALTHCARE (Total Return Index)
    Source: Fund FactSheet

    Disclaimer: NO INVESTMENT ADVICE. The Content is for informational purposes only.